Xbrane Biopharma Q3 2022: Initial Comment on Report - Redeye

Redeye remains positive on the investment case in Xbrane Biopharma following its Q3 2022 report. Only a few weeks remain until the anticipated approval of Ximluci from the European Commission, and in turn, the Q1 2023 launch in Europe is nearing. We leave our comments.

Länk till analysen i sin helhet: https://www.redeye.se/research/860444/xbrane-biopharma-q3-2022-initial-comment-on-report?utm_source=finwire&utm_medium=RSS